Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
William Blair Investment Management, LLC reported its beneficial ownership position in Twist Bioscience Corp common stock. The firm reported beneficial ownership of 2,174,594 shares, representing 3.5% of the outstanding common stock. It has sole voting power over 1,975,454 shares and sole dispositive power over all 2,174,594 shares, with no shared voting or dispositive power. The filing indicates that the holder now owns 5 percent or less of the class of Twist Bioscience common stock. The reporting person is organized in Delaware and signed the report through its Chief Compliance Officer, Telmo Martins.
Twist Bioscience Corp director Robert Chess exercised options for 18,417 shares of common stock on August 7, 2026 at an exercise price of $11.89 per share and sold the same 18,417 shares at $110.89 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following these transactions, an entity associated with Chess, the Chess 1997 Trust, held 42,528 shares of common stock indirectly, with Chess and his spouse serving as sole trustees and beneficiaries.
TWST shareholder Emily M. Leproust filed a notice of proposed sale of 113,318 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $14,183,056.89, to be sold on or after 08/10/2026 on NASDAQ. Shares outstanding were 62,707,424 as of 08/10/2026; this is a baseline figure, not the amount being offered. The filing also lists multiple open-market sales of common stock during the prior three months, including transactions on 05/21/2026, 05/26/2026, 05/27/2026, 05/28/2026, 06/08/2026, 06/22/2026, 06/25/2026, and 08/03/2026.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 14,205 shares of common stock on August 5, 2026 at an average price of $109.75 per share. The sale was executed in an open market or private transaction under a pre‑arranged Rule 10b5-1 trading plan adopted on February 17, 2026.
Following this transaction, Cho directly owns 89,866 Twist Bioscience shares.
FMR LLC has reported beneficial ownership of common stock of Twist Bioscience Corp. As of June 30, 2026, FMR LLC beneficially owned 4,703,044.11 shares of Twist Bioscience common stock, representing 7.6% of the class.
FMR LLC has sole dispositive power over 4,703,044.11 shares and sole voting power over 4,701,268.00 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person, with sole dispositive power over 4,703,044.11 shares and no voting power. One or more other persons may have rights to dividends or sale proceeds, but no such person holds more than five percent of the outstanding common stock.
Twist Bioscience Corporation entered into an underwriting agreement for a primary public offering of 3,125,000 shares of common stock at $96.00 per share, with underwriters granted a 30-day option for up to 468,750 additional shares, which has been exercised in full.
The transaction, conducted under Twist’s automatic shelf registration, is expected to generate approximately $327.1 million in net proceeds after underwriting discounts and expenses, with closing anticipated on August 6, 2026, subject to customary conditions. Twist plans to use the proceeds, together with existing cash, to fund research and development, expand manufacturing capacity, support product offerings, and for working capital and other general corporate purposes.
Twist Bioscience Corporation is conducting a primary offering of 3,125,000 shares of common stock at $96.00 per share, for gross proceeds of $300,000,000 and estimated net proceeds of $284.3 million after underwriting fees and expenses. Underwriters have a 30‑day option to buy up to 468,750 additional shares. Shares outstanding will be 65,799,150 after the offering, excluding the option.
Management plans to use the cash, together with existing resources, to fund research and development, expand manufacturing capacity, support product offerings, and for working capital and other general corporate purposes, with potential but uncommitted in‑licensing or acquisitions. For the quarter ended June 30, 2026, Twist reported $118.4 million in revenue, a $35.1 million net loss (or $0.56 per diluted share), and adjusted EBITDA of $(11.3) million.
The company estimates an immediate increase in net tangible book value from $5.60 to $9.65 per share, implying $86.35 per‑share dilution to new investors at the offering price. Existing equity plans and an unused $200.0 million at‑the‑market program represent additional potential future issuances.
Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 2,888 shares of common stock on August 3, 2026 at an average price of $85.3212 per share to cover tax withholding from vesting Restricted Stock Units. These shares were sold under a required “sell to cover” election and are not discretionary trades. After this transaction, he directly holds 269,678 shares of common stock.